A combination therapy of Vidaza (azacitidine) and valproic acid (Depakene) may be more effective than Vidaza alone for the treatment of myelodysplastic syndromes (MDS), according to a Phase 2 study published in the journal Clinical Cancer Research.
Valproic acid is commonly used to reduce seizures in epilepsy patients and to treat bipolar disorder. It has recently become of interest as a possible treatment for blood- and bone marrow-related cancers like MDS.
Previous studies have shown that two classes of drugs,…
FDA Declines To Approve Clolar As Treatment For Adult AML Patients – On October 6, Genzyme Corporation reported that the FDA has declined to approve the company’s application to market Clolar (clofarabine) as a treatment for adult acute myeloid leukemia (AML) patients. Clolar is currently approved for the treatment of children with acute lymphoblastic leukemia who have relapsed or failed to respond to at least two other drugs. Genzyme says that the FDA is recommending a randomized, controlled clinical study of Clolar in adult AML patients as a condition for approving Clolar’s use in those…